Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Fortrea Holdings Inc. (FTRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: FTRE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.12
1 Year Target Price $8.12
| 0 | Strong Buy |
| 1 | Buy |
| 10 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.92% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 917.08M USD | Price to earnings Ratio - | 1Y Target Price 8.12 |
Price to earnings Ratio - | 1Y Target Price 8.12 | ||
Volume (30-day avg) 12 | Beta 1.89 | 52 Weeks Range 3.97 - 25.28 | Updated Date 09/14/2025 |
52 Weeks Range 3.97 - 25.28 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.57% | Operating Margin (TTM) -1.54% |
Management Effectiveness
Return on Assets (TTM) -1.42% | Return on Equity (TTM) -100.49% |
Valuation
Trailing PE - | Forward PE 6.43 | Enterprise Value 2076880000 | Price to Sales(TTM) 0.34 |
Enterprise Value 2076880000 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 0.76 | Enterprise Value to EBITDA 92.35 | Shares Outstanding 90800000 | Shares Floating 83895568 |
Shares Outstanding 90800000 | Shares Floating 83895568 | ||
Percent Insiders 0.5 | Percent Institutions 111.46 |
Upturn AI SWOT
Fortrea Holdings Inc.
Company Overview
History and Background
Fortrea Holdings Inc. (FTRE) was spun off from Laboratory Corporation of America Holdings (Labcorp) and began trading independently on July 3, 2023. It evolved from Labcorp's Clinical Development segment, providing comprehensive clinical trial management and related services to biopharmaceutical companies.
Core Business Areas
- Clinical Development Services: Fortrea provides comprehensive clinical development services, including Phase I-IV clinical trials, bioanalytical laboratory services, and regulatory consulting, supporting biopharmaceutical companies in bringing new therapies to market.
Leadership and Structure
Raymond F. Huml serves as the CEO. The organizational structure is based on functional units focused on clinical development services and supporting functions like finance, legal, and HR.
Top Products and Market Share
Key Offerings
- Phase I-IV Clinical Trials: Managing and executing clinical trials across all phases of drug development. Market share within the CRO industry is competitive. Competitors: IQVIA, PPD (Thermo Fisher Scientific), ICON, Syneos Health. Hard to ascertain market share percentage
- Bioanalytical Laboratory Services: Analyzing biological samples to support clinical trials. Competitors include: ICON, PPD (Thermo Fisher Scientific). Hard to ascertain market share percentage
Market Dynamics
Industry Overview
The clinical research organization (CRO) industry is experiencing growth driven by increasing R&D spending in the pharmaceutical and biotechnology sectors, rising demand for outsourcing, and the increasing complexity of clinical trials.
Positioning
Fortrea is positioned as a large CRO providing end-to-end clinical trial management services. Its competitive advantage lies in its experience and comprehensive service offerings. It aims to be a top-tier, pure-play CRO.
Total Addressable Market (TAM)
The global CRO market is estimated to be around $75-80 billion. Fortrea is positioned to capture a portion of this market by focusing on its core competencies and expanding its service offerings.
Upturn SWOT Analysis
Strengths
- Comprehensive service offerings
- Global reach
- Experienced management team
- Strong reputation (derived from Labcorp)
- Focus on clinical development
Weaknesses
- Relatively new independent company
- Integration challenges post-spin-off
- Potential for higher operating costs as a standalone entity
- Dependence on the pharmaceutical and biotechnology industries
Opportunities
- Growing demand for outsourced clinical research
- Expansion into new geographic markets
- Adoption of new technologies (e.g., AI, data analytics)
- Strategic acquisitions to expand service offerings
Threats
- Intense competition from other CROs
- Economic downturn affecting R&D spending
- Changes in regulatory requirements
- Consolidation in the pharmaceutical industry
- Pricing pressure
Competitors and Market Share
Key Competitors
- IQV
- TMO
- ICLR
- SYNH
Competitive Landscape
Fortrea faces strong competition from established players in the CRO industry. To succeed, it needs to differentiate itself through service quality, innovation, and client focus. Fortrea also needs to successfully navigate integration challenges and establish its own brand identity.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited since spin-off in July 2023.
Future Projections: Future projections will be heavily influenced by execution of strategy post spin off
Recent Initiatives: Focus on improving operational efficiency, expanding service offerings, and building strong relationships with biopharmaceutical clients.
Summary
Fortrea, a spin-off from Labcorp, is a relatively new pure-play CRO operating in a growing industry. It has strengths in its comprehensive service offerings and experience, but faces challenges related to integration and competition. Its success depends on executing its growth strategy and differentiating itself in the market. Investors should monitor its financial performance and strategic initiatives closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share estimations are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortrea Holdings Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2023-07-03 | CEO & Director Mr. Anshul Thakral | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14500 | Website https://www.fortrea.com |
Full time employees 14500 | Website https://www.fortrea.com | ||
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.